 | |
| Clinical data | |
|---|---|
| Other names | N6-[(S)-1-(Phenyl)propyl]adenosine |
| Drug class | Adenosine receptor agonist;Sedative;Hypnotic |
| ATC code |
|
| Identifiers | |
| |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C19H23N5O4 |
| Molar mass | 385.424 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
YZG-331, also known asN6-[(S)-1-(phenyl)propyl]adenosine, is anadenosine receptor agonist which is or was under investigation for the potential treatment ofinsomnia.[1][2][3]
The drug appears to act through theadenosineA1 andA2A receptors.[3] It producessedative andhypnotic effects andhypolocomotion in animals.[3] The drug isorally active and crosses theblood–brain barrier, although itsintestinalabsorption andcentralpermeability may be reduced by itsP-glycoproteinsubstrate activity.[4][5] It is asyntheticderivative ofadenosine and ofN6-(4-hydroxybenzyl)adenine riboside (NHBA).[5][3] The latter compound is found in thetraditional Chinese medicinalherbGastrodia elata.[5][3]
YZG-331 was first described in thescientific literature by at least 2014.[6] As of 2025, it has reached thepreclinical research stage of development.[1]
1. Adenosine Receptor Agonist. YZG-331 is a promising sedative hypnotic and adenosine analog that exerts its effects by binding to the adenosine receptor. (See the Other Receptors section for a review of the pharmacology of A1A and A2A.)